Svetlana Nikic, Founder of Precision Oncology Consulting, shared a post on LinkedIn:
“Are you looking into insights related to ctDNA MRD adoption across the US?
Minimal residual disease (MRD) testing and ctDNA monitoring are transforming oncology care – but adoption patterns, physician perceptions, and panel preferences remain complex.
I’m excited to share that I’ve partnered with a specialist MedTech research group to bring you one of the most detailed syndicated studies on MRD to date.
Unlike the broad, high-level market forecasts you might see from other consultancies, this report delivers real-world, physician-level insights, including:
- Actual MRD test ordering volumes by tumor type and stage (NSCLC, breast, CRC, prostate, bladder, ovarian)
- What drives oncologists’ panel choices – reimbursement, turnaround time, utility data, hospital contracts, sales rep engagement
- Reasons physicians switch from one MRD/monitoring assay to another
- Panel-by-panel satisfaction and Net Promoter Scores (unique in the space)
- and last but not least, access to an interactive dashboard for further analytics and a data deep dive.
This goes beyond ‘market sizing’ to uncover the why behind oncologist adoption and switching. insights directly applicable to pharma and diagnostics teams shaping launch, messaging, and market access strategies.
If you would like to learn more or receive a Sample Report of the study, message me.”
More posts featuring Svetlana Nikic.